clinical trial · NCT05646381
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Aortic StenosisPelacarsen (TQJ230) 80mgMatching placebo
brief summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.
started
Mar 7, 2024
primary completion
Mar 12, 2030
completion
Mar 12, 2030
last updated
Apr 15, 2026
official title
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol